Market Overview

PureTech Health Collaborator Publishes in Journal Nature Regarding New Insights into Key Role of Brain Lymphatics in Alzheimer's and Other Neurodegenerative Diseases

Share:

Related intellectual property exclusively licensed to PureTech Health
and being advanced as part of growing internal research and development
division

PureTech Health plc (LSE: PRTC) ("PureTech Health"), a clinical-stage
biopharmaceutical company developing novel medicines for dysfunctions of
the Brain-Immune-Gut (BIG), today notes the publication of foundational
science in Nature
which underlies its new internal program focused on treating central
nervous system (CNS) disorders via modulation of the brain's lymphatic
system.

The approach is based on the work of Jonathan Kipnis, Ph.D., Harrison
Distinguished Teaching Professor and Chair, Department of Neuroscience,
and Director, Centre for Brain Immunology and Glia, at the University of
Virginia School of Medicine. In 2015, Dr. Kipnis published his original
discovery of lymphatic vessels in the brain in Nature.
Building on that discovery, Dr. Kipnis' latest publication reveals the
potential role of these lymphatic vessels, including in Alzheimer's
disease, Huntington's disease, and age-associated cognitive decline. The
publication presents preclinical models that suggest modulation of
lymphatic function in the brain may prevent or delay diseases associated
with aging.

"Dr. Kipnis' original work completely changed the way we view immune
privilege in the brain – the unique biological properties that protect
certain areas of the body from inflammatory immune responses," said
Joseph Bolen, Ph.D., Chief Scientific Officer at PureTech Health. "This
new discovery once again offers novel insights into the lymphatics' role
in maintaining brain homeostasis and suggests that neurodegeneration may
be tied to drainage issues in the brain. Because neurodegeneration is
associated with so many devastating conditions, these findings provide
us with a unique opportunity to develop treatments that address one of
the world's highest global disease burdens."

PureTech Health has exclusively licensed this intellectual property from
the University of Virginia (UVA) Licensing & Ventures Group and is
developing it in collaboration with Dr. Kipnis at UVA and as a part of
PureTech's internal research and development division, which is focused
on lymphatics and immune cell trafficking.

Dr. Kipnis commented on this announcement, "Our work exploring the
function of lymphatic vessels has shed light on novel therapeutic
approaches that complement the lymphatics focus of PureTech's research
and development work. I look forward to building on a great partnership
with the team at PureTech Health to further advance these findings and
translate them into first-in-class therapies that could fundamentally
change the way we intervene in neurodegenerative disease."

PureTech's Internal division is advancing a pipeline fueled by recent
discoveries in lymphatics and immune cell trafficking to modulate
disease in a tissue-specific manner. This division, which includes the
CNS lymphatics technology, has generated compelling pre-clinical data
and secured key intellectual property for its lymphatic and immune cell
trafficking programs.

About the CNS Lymphatics Technology
The central nervous
system (CNS) was previously thought to be devoid of lymphatic
vasculature; however, research published in Nature
in 2015 identified the meningeal lymphatic and glymphatic systems as
key maintenance organs within the brain. The biological crosstalk at the
CNS-immune interface has been further supported by evidence published in Nature
in 2018, which demonstrated that modulation of lymphatic function in
the brain may potentially prevent or delay diseases associated with
neurodegeneration, including Alzheimer's disease, Huntington's disease,
and age-associated cognitive decline. These insights underlie PureTech's
approach to designing novel categories of therapeutics to address
debilitating and devastating CNS disorders.

About PureTech Health
PureTech Health (LSE: PRTC) is an
advanced, clinical-stage biopharmaceutical company developing novel
medicines for dysfunctions of the Brain-Immune-Gut (BIG). The Company
has developed deep insight into the connection between these systems and
the resulting role in many chronic diseases, which represent the
majority of healthcare spend and have proven resistant to established
therapeutic approaches. By harnessing this emerging field of human
biology, PureTech Health has developed new categories of medicines with
the potential to have great impact on people with serious diseases.

PureTech Health is advancing a rich pipeline of innovative therapies
across two divisions. Its Affiliates division includes two product
candidates that are preparing for potential regulatory approval in the
United States and Europe and a number of clinical and pre-clinical
programs. These affiliates have developed ground-breaking platforms and
therapeutic candidates in collaboration with some of the world's leading
scientific experts.

PureTech's Internal division (Ariya) is advancing a pipeline fueled by
recent discoveries in lymphatics and immune cell trafficking to modulate
disease in a tissue-specific manner. These programs build on a new
understanding of the transport and biodistribution of various immune
system components in order to develop targeted therapies for diseases
with major unmet needs including cancer and autoimmune and neuroimmune
disorders. One of these programs, which is focused on the oral
administration of nucleic acids and other biologics using milk exosomes,
is being advanced in collaboration with Roche for the potential
application across their antisense oligonucleotides platform.

For more information, visit www.puretechhealth.com or
connect with us on Twitter @puretechh.

Forward Looking Statement
This press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company's future prospects, developments
and strategies. The forward-looking statements are based on current
expectations and are subject to known and unknown risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from current expectations, including,
but not limited to, those risks and uncertainties described in the risk
factors included in the regulatory filings for PureTech Health plc.
These forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each forward-looking
statement speaks only as at the date of this press release. Except as
required by law and regulatory requirements, neither the company nor any
other party intends to update or revise these forward-looking
statements, whether as a result of new information, future events or
otherwise.

View Comments and Join the Discussion!